PlainRecalls
FDA Drug Critical Class I Terminated

Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.

Reported: January 26, 2022 Initiated: January 5, 2022 #D-0462-2022

Product Description

Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.

Reason for Recall

Labeling: Missing Label: label missing from some Semglee prefilled pens.

Details

Recalling Firm
Mylan Pharmaceuticals Inc
Units Affected
73,175 prefilled pens
Distribution
Nationwide in the USA and Thailand.
Location
Morgantown, WV

Frequently Asked Questions

What product was recalled?
Semglee (insulin glargine) injection, 100 units/mL (U-100), 3 mL Prefilled Pen (NDC 49502-0196-71), packaged in Five 3 mL Prefilled Pens per carton (NDC 49502-0196-75), Rx only, Manufactured in Malaysia for: Mylan Specialty L.P., Morgantown, WV, 26505.. Recalled by Mylan Pharmaceuticals Inc. Units affected: 73,175 prefilled pens.
Why was this product recalled?
Labeling: Missing Label: label missing from some Semglee prefilled pens.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 26, 2022. Severity: Critical. Recall number: D-0462-2022.